ES2158778B1 - Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2158778B1
ES2158778B1 ES009900849A ES9900849A ES2158778B1 ES 2158778 B1 ES2158778 B1 ES 2158778B1 ES 009900849 A ES009900849 A ES 009900849A ES 9900849 A ES9900849 A ES 9900849A ES 2158778 B1 ES2158778 B1 ES 2158778B1
Authority
ES
Spain
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
compounds
salt compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009900849A
Other languages
English (en)
Other versions
ES2158778A1 (es
Inventor
Andrew Simon Craig
Alan David Jones
Deirdre O'keeffe
Neal Ward
Victor Witold Jacewicz
Michael Urquhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2158778(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of ES2158778A1 publication Critical patent/ES2158778A1/es
Application granted granted Critical
Publication of ES2158778B1 publication Critical patent/ES2158778B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de sales de paroxetina, su preparación y uso, y composiciones farmacéuticas que los contienen. Los compuestos comprende metanosulfonato de paroxetina en forma cristalina. El procedimiento comprende cristalizar o recristalizar una solución de metanosulfonato de paroxetina en un disolvente. Los compuestos pueden usarse en la preparación de un medicamento. Las composiciones comprenden metanosulfonato de paroxetina y un vehículo farmacéuticamente aceptable. La invención es aplicable al tratamiento y/o prevención de alcoholismo, depresión, ansiedad, anorexia y otros trastornos médicos.
ES009900849A 1998-07-02 1999-04-23 Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. Expired - Fee Related ES2158778B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (2)

Publication Number Publication Date
ES2158778A1 ES2158778A1 (es) 2001-09-01
ES2158778B1 true ES2158778B1 (es) 2002-03-16

Family

ID=27269380

Family Applications (4)

Application Number Title Priority Date Filing Date
ES009900849A Expired - Fee Related ES2158778B1 (es) 1998-07-02 1999-04-23 Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
ES99918159T Expired - Lifetime ES2209428T3 (es) 1998-07-02 1999-04-23 Un solvato 1:1 de metanosulfonato de pparoxetina con acetonitrilo.
ES99303151T Expired - Lifetime ES2149044T3 (es) 1998-07-02 1999-04-23 Metanosulfonato de paroxetina.
ES00201290T Expired - Lifetime ES2157881T3 (es) 1998-07-02 2000-04-10 Metanosulfonato de paroxetina.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES99918159T Expired - Lifetime ES2209428T3 (es) 1998-07-02 1999-04-23 Un solvato 1:1 de metanosulfonato de pparoxetina con acetonitrilo.
ES99303151T Expired - Lifetime ES2149044T3 (es) 1998-07-02 1999-04-23 Metanosulfonato de paroxetina.
ES00201290T Expired - Lifetime ES2157881T3 (es) 1998-07-02 2000-04-10 Metanosulfonato de paroxetina.

Country Status (34)

Country Link
US (4) US6063927A (es)
EP (5) EP1020464B1 (es)
JP (1) JP2002519422A (es)
KR (1) KR20010053336A (es)
CN (1) CN1127502C (es)
AR (2) AR011759A1 (es)
AT (4) AT3185U3 (es)
AU (4) AU713877B3 (es)
BE (3) BE1011664A6 (es)
BR (1) BR9911682A (es)
CA (1) CA2269999A1 (es)
CH (1) CH689805A8 (es)
DE (5) DE29907248U1 (es)
DK (7) DK199900554A (es)
ES (4) ES2158778B1 (es)
FI (2) FI112077B (es)
FR (2) FR2780728B1 (es)
GB (5) GB2339428A (es)
GR (3) GR990100140A (es)
HU (1) HUP0102334A3 (es)
IE (5) IE20000633A1 (es)
IL (1) IL140628A (es)
IT (1) IT1312540B1 (es)
LU (1) LU90388B1 (es)
NL (4) NL1011875C2 (es)
NO (1) NO319030B1 (es)
NZ (1) NZ509180A (es)
PL (1) PL345214A1 (es)
PT (4) PT102291B (es)
SE (1) SE9901462A0 (es)
SI (3) SI1020464T1 (es)
SK (1) SK20262000A3 (es)
TR (1) TR200100054T2 (es)
WO (1) WO2000001694A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP4081820B2 (ja) * 1997-02-27 2008-04-30 味の素株式会社 晶析装置及び晶析方法
EE03970B1 (et) * 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
EP1313474A2 (en) * 2000-08-28 2003-05-28 Synthon B.V. Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CA2603832C (en) * 2005-04-07 2011-11-22 Xy, Inc. Flow path conditioner system
WO2007058998A2 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008112479A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Salts of 3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-i-yl) -quinazolin-4-yl] -pyrrole-2, 5-di one
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (es) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
BR9608471A (pt) * 1995-05-17 1998-12-29 Novo Nordisk As Processo para a preparação de um composto
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (en) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Process for preparing crystalline paroxetin hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
EE03970B1 (et) * 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
CA2319652A1 (en) * 1998-02-06 1999-08-12 Michael Urquhart Salts of paroxetine
IL138390A0 (en) * 1998-03-16 2001-10-31 Smithkline Beecham Plc Crystalline form of paroxetine
AP2000001950A0 (en) * 1998-04-09 2000-12-31 Smithkline Beecham Plc Paroxetine maleate.
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
FI4209U1 (fi) 1999-11-10
LU90388B1 (fr) 2001-01-29
NL1011875C2 (nl) 2000-03-24
GR990100140A (el) 2000-03-31
SI1020464T1 (en) 2001-12-31
ITMI990866A1 (it) 2000-10-23
AR018197A1 (es) 2001-10-31
GR3034328T3 (en) 2000-12-29
PT102291A (pt) 2000-05-31
EP1089996A1 (en) 2001-04-11
DK1089996T3 (da) 2004-02-09
IT1312540B1 (it) 2002-04-22
AU2392899A (en) 2000-01-20
JP2002519422A (ja) 2002-07-02
BE1012420A6 (fr) 2000-10-03
IES20000893A2 (en) 2001-05-30
SI1089996T1 (en) 2004-04-30
DE29907248U1 (de) 1999-09-09
GB9909505D0 (en) 1999-06-23
NL1012272C1 (nl) 1999-07-12
CN1127502C (zh) 2003-11-12
NO991944D0 (no) 1999-04-23
DK0970955T3 (da) 2000-10-09
NL1012271C2 (nl) 1999-09-23
BE1012403A5 (fr) 2000-10-03
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
AR011759A1 (es) 2000-09-13
DK199900234U1 (da) 2000-12-22
DE69911774D1 (de) 2003-11-06
GR3036208T3 (en) 2001-10-31
GB2352395A (en) 2001-01-31
SE9901462L (es)
DE60000003T2 (de) 2002-03-21
FI990922A0 (fi) 1999-04-23
SE9901462D0 (sv) 1999-04-23
TR200100054T2 (tr) 2001-06-21
HUP0102334A3 (en) 2003-12-29
AU713131B3 (en) 1999-11-25
CH689805A5 (fr) 1999-11-30
NZ509180A (en) 2001-06-29
EP1089996B1 (en) 2003-10-01
DE19918588A1 (de) 2000-01-27
FIU990190U0 (fi) 1999-04-23
EP1020464A1 (en) 2000-07-19
ES2158778A1 (es) 2001-09-01
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
HK1037877A1 (en) 2002-02-22
DK1020464T3 (da) 2001-09-24
CH689805A8 (fr) 2000-02-29
DE69900007D1 (de) 2000-09-07
PL345214A1 (en) 2001-12-03
US20020193406A1 (en) 2002-12-19
SK20262000A3 (sk) 2001-07-10
EP0970955B1 (en) 2000-08-02
US20010023253A1 (en) 2001-09-20
GB2377637A (en) 2003-01-22
GB2336364B (en) 2000-05-10
AU713877B3 (en) 1999-12-09
ATE251155T1 (de) 2003-10-15
CN1315949A (zh) 2001-10-03
ATE195121T1 (de) 2000-08-15
AT3185U2 (de) 1999-11-25
NO319030B1 (no) 2005-06-06
KR20010053336A (ko) 2001-06-25
FR2802098A1 (fr) 2001-06-15
DK199900234U4 (da) 2000-12-22
EP1288214A1 (en) 2003-03-05
NO991944L (no) 2000-01-03
GR1003350B (el) 2000-03-29
IE20000633A1 (en) 2001-10-17
EP1020463A1 (en) 2000-07-19
NL1011875A1 (nl) 2000-01-07
AU732211B2 (en) 2001-04-12
BE1011664A6 (fr) 1999-11-09
FR2780728A1 (fr) 2000-01-07
IE990344A1 (en) 2000-05-03
SE9901462A0 (sv) 2000-01-03
FI990922L (fi) 2000-01-03
IES20000894A2 (en) 2001-05-30
GB9920332D0 (en) 1999-11-03
ES2209428T3 (es) 2004-06-16
AT3185U3 (de) 2000-01-25
ATE202777T1 (de) 2001-07-15
IES81166B2 (en) 2000-05-31
US20020035130A1 (en) 2002-03-21
DE60000003D1 (de) 2001-08-09
GB0026487D0 (en) 2000-12-13
GB2336364A (en) 1999-10-20
PT1020464E (pt) 2001-10-30
IL140628A0 (en) 2002-02-10
AU732211C (en) 2004-05-06
PT970955E (pt) 2000-11-30
US6063927A (en) 2000-05-16
EP1020464B1 (en) 2001-07-04
ES2157881T3 (es) 2001-09-01
SI0970955T1 (en) 2001-02-28
WO2000001694A1 (en) 2000-01-13
FR2780728B1 (fr) 2001-02-16
HUP0102334A2 (hu) 2002-05-29
DE69911774T2 (de) 2004-08-05
PT102291B (pt) 2002-07-31
BR9911682A (pt) 2001-12-26
ES2149044T3 (es) 2000-10-16
DK199900176U3 (da) 1999-08-13
GB2339428A (en) 2000-01-26
DK199900554A (da) 2000-01-03
IES990343A2 (en) 2000-01-02
NL1011874C1 (nl) 1999-07-12
FI112077B (fi) 2003-10-31
GB2352395B (en) 2004-02-11
DE69900007T2 (de) 2001-06-07
AU3619199A (en) 2000-01-24
GB2367003A (en) 2002-03-27
DK200000390U1 (da) 2000-12-27
IL140628A (en) 2004-06-20
EP0970955A1 (en) 2000-01-12
CA2269999A1 (en) 2000-01-02

Similar Documents

Publication Publication Date Title
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ES2160648T3 (es) Derivados de piridina.
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
ATE229017T1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
AR034897A1 (es) Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
BR0108456A (pt) Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
AR025962A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que los contienen
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
ES2061848T3 (es) Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
IT1205729B (it) Derivati di diidrobenzofurano-e cromano-carbossammidi,procedimento per prepararli e loro impiego come neurolettici
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
BR0010693A (pt) Derivados azaindol para tratamento de depressão
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR036131A1 (es) Derivados de benzo (g) quinolina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la fabricacion de un medicamento
MX9401080A (es) Compuestos heteroaromaticos.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010120

Kind code of ref document: A1

Effective date: 20010120

FD1A Patent lapsed

Effective date: 20101018